Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning — See source for full details.
$ALT
Price history, market instrument context, member research, and related headlines in one place.
ALT key statistics
NasdaqGMUSD
52-week range
$2.290%$6.44
Latest session $2.29–$2.41Altimmune, Inc. (ALT) is a stock instrument quoted on NasdaqGM in USD. The most recently published price is $2.31, down $0.12 (4.94%) from the previous close of $2.43. It has traded between $2.29 and $2.41 in the latest session. Over the past year it has ranged from $2.29 to $6.44, leaving it trading near the bottom of its 52-week range. Reported volume for the session was 5.6M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Altimmune Q2 2026 Earnings Preview — See source for full details.
Altimmune stock surges 18% on positive trial results — See source for full details.
Loading $ALT research…